Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Serum Fetuin Level in Polycystic Ovary Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03819998
Recruitment Status : Unknown
Verified August 2019 by Aljazeera Hospital.
Recruitment status was:  Recruiting
First Posted : January 29, 2019
Last Update Posted : August 6, 2019
Sponsor:
Collaborators:
Cairo University
National Research Centre, Egypt
Information provided by (Responsible Party):
Aljazeera Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
polycystic ovary syndrome is a common gynecological problem

Condition or disease Intervention/treatment
Polycystic Ovary Diagnostic Test: measurement of Fetuin-A level in serum

Detailed Description:
Understanding the pathophysiology and the cause is of much importance for proper management of this problem
Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 50 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: Serum Fetuin Level as a Marker in Polycystic Ovary Syndrome
Actual Study Start Date : January 30, 2019
Estimated Primary Completion Date : February 1, 2020
Estimated Study Completion Date : February 5, 2020

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
PCOS group
women who have PCOS
 Diagnostic Test: measurement of Fetuin-A level in serum
Fetuin A level will be measured in blood of the PCOS women
Other Name: Fwtuin A level
control group
women who donnot have PCOS
 Diagnostic Test: measurement of Fetuin-A level in serum
Fetuin A level will be measured in blood of the PCOS women
Other Name: Fwtuin A level


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The number of women who will have high level of fetuin A and has PCOS [ Time Frame: within a week ]
    Evaluation of women who have PCOS in relation to fetuin A level


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 42 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Women with polycystic ovary syndrome
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
women who have PCOS and have symptoms of hyperandrogenism and irregular cycles
Criteria

Inclusion Criteria:

  • women who have PCOS in group 1 and who donnot have PCOS in group 2 with age between 20 -42 years

Exclusion Criteria:

  • women above 42 years old
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03819998


Contacts
Layout table for location contacts
Contact: Mahmoud Alalfy, PhD 01002611058 mahmoudalalfy@ymail.com

Locations
Layout table for location information
Egypt
Algazeerah and Kasralainy hospital Recruiting
Giza, Egypt
Contact: Mahmoud Alalfy, master    +201002611058    mahmoudalalfy@ymail.com   
Contact: Ahmed Elgazzar, M.D    +201014005959      
Principal Investigator: Mahmoud Alalfy, master         
Sponsors and Collaborators
Aljazeera Hospital
Cairo University
National Research Centre, Egypt
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Aljazeera Hospital
ClinicalTrials.gov Identifier: NCT03819998    
Other Study ID Numbers: Fetuin
First Posted: January 29, 2019    Key Record Dates
Last Update Posted: August 6, 2019
Last Verified: August 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Polycystic Ovary Syndrome
Ovarian Cysts
Cysts
Neoplasms
 Ovarian Diseases
Adnexal Diseases
Gonadal Disorders
Endocrine System Diseases